Pharma companies say new US drug price law leaves them in limbo
Is the pharma industry crying wolf when it says that President Joe Biden’s Inflation Reduction Act will hurt innovation? Though companies’ priorities are staying the same, strategies might change.
By Ike Swetlitz and Angelica Peebles, bloomberg
Drugmakers say a new US law aimed at cutting prices on top-selling medicines after they’ve been on the market for several years has them stuck in limbo.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
